Exenatide Groups

The groups are held in the Diabetes Centre at Queen Alexandra Hospital once a week on a Tuesday morning. Up to six patients are able to attend the group which consists of three education sessions with a Diabetes Specialist Nurse and two telephone consultations over a six month period.Exenatide is initiated at the first group session.

Patients are monitored throughout this period of time in respect of weight, glycaemic control, blood pressure, lipid status and general well being. These sessions are designed to help patients understand the best way of using Exenatide and enable them to share their experiences whilst receiving this treatment.

WHAT IS EXENATIDE 

Exenatide (Byetta) is a GLP-1 mimetic. GLP-1 is one of the incretin hormones which is secreted within minutes of food intake and assists in regulating glucose levels.

Exenatide is administered by subcutaneous injection twice a day prior to breakfast and evening meal.  

Exenatide - Patient pathway for use:

Type 2 Diabetes with inadequate control despite maximally tolerated doses of 2-3 oral hypoglycaemic agents.

HBA1c>7.5%

BMI >27kg/m2 and gaining weight.

 Exenatide is sometimes used in combination with insulin therapy after careful risk benefit analysis.

 If you have any patients that fulfil the criteria for use with Exenatide, we would welcome any referrals.

If you would like to discuss your patients eligibility for a trial of Exenatide please contact the Dr Iain Cranston / DSN Sharon Allard / DSN Sarah Moutter on 023 9228 6260.